Nanjing Leads Biolabs Co., Ltd. (HKG: 9887) announced that LBL‑024 has been granted Fast Track Designation by the U.S. Food and Drug Administration (FDA) for the first-line treatment of advanced biliary tract cancer (BTC). This marks the second FDA Fast Track Designation for LBL‑024, following the earlier designation in extrapulmonary neuroendocrine carcinoma (EP‑NEC) — further elevating the profile of the bispecific antibody targeting PD‑L1 and 4‑1BB, which has the potential to become the world’s first approved 4‑1BB antibody drug.
Contents
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | U.S. Food and Drug Administration (FDA) |
| Designation Type | Fast Track Designation (second for LBL‑024) |
| Product | LBL‑024 – bispecific PD‑L1 × 4‑1BB antibody |
| Designated Indication | First-line treatment of advanced biliary tract cancer (BTC) |
| Prior Designation | Fast Track for extrapulmonary neuroendocrine carcinoma (EP‑NEC) |
| Announcement Date | 12 Oct 2026 |
| China Regulatory Status | BLA included in NMPA priority review and approval procedure (July 2026); officially accepted (August 2026) |
Drug Profile & Mechanism of Action
- Molecule: LBL‑024, a bispecific antibody developed by Leads Biolabs.
- Targets: PD‑L1 (immune checkpoint ligand) and 4‑1BB (CD137, a costimulatory immune receptor) — engaged simultaneously in a single molecule.
- Dual Mechanism Concept: PD‑L1 blockade releases the brakes on T-cell activity, while 4‑1BB agonism delivers a costimulatory activation signal — a combination designed to deepen and sustain antitumor immunity.
- Cold Tumor Strategy: The program explicitly targets cold tumors — malignancies with limited immune infiltration that typically respond poorly to checkpoint inhibition alone.
- Clinical Breadth: Clinical studies have been conducted across 14 indications, covering multiple major cancer types.
- First-in-Class Potential: LBL‑024 has the potential to become the world’s first approved 4‑1BB antibody drug, the world’s first agonist antibody drug, and the world’s first therapeutic drug for EP‑NEC.
Regulatory Progress – Dual-Track Momentum
- FDA Fast Track (BTC): The designation in first-line advanced BTC provides the program with more frequent FDA communication and potential expedited development tools in a setting of high unmet need.
- FDA Fast Track (EP‑NEC): The earlier Fast Track in extrapulmonary neuroendocrine carcinoma addresses a tumor type with no established targeted therapy — where LBL‑024 could become the world’s first therapeutic drug.
- NMPA Priority Review: In July 2026, the Biologics License Application (BLA) for LBL‑024 was included in the priority review and approval procedure by China’s National Medical Products Administration (NMPA); the BLA was officially accepted in August 2026 — positioning China as a potential first-approval market.
- Indication-Specific Details: The BLA’s specific indication, trial basis, and target action dates were not disclosed in the announcement.
Disease & Treatment Context
- Biliary Tract Cancer: BTC — encompassing cholangiocarcinoma and gallbladder cancer — is an aggressive malignancy typically diagnosed at advanced stages; first-line systemic therapy has historically centered on chemotherapy plus immunotherapy, with substantial remaining unmet need.
- EP‑NEC: Extrapulmonary neuroendocrine carcinoma is a rare, highly aggressive malignancy with limited treatment options and no approved disease-specific therapy, making any effective agent potentially practice-defining.
- The 4‑1BB Challenge: Systemic 4‑1BB agonism has long been pursued in immuno-oncology but has faced hepatic toxicity hurdles with earlier agents; a bispecific design engaging 4‑1BB in the context of PD‑L1 targeting represents an attempt to widen the therapeutic window. (Class background; LBL‑024-specific safety data were not disclosed in the announcement.)
Market Impact & Outlook
- First-in-Class Positioning: If approved, LBL‑024 would establish Leads Biolabs as the originator of an entirely new antibody class — the first 4‑1BB-containing and first agonist antibody drug on the market.
- Multi-Indication Optionality: With studies spanning 14 indications and two FDA Fast Track designations, the asset carries broad label-expansion potential across cold and major tumor types.
- China–US Dual Pathway: Parallel NMPA priority review of the BLA and FDA Fast Track engagement give the program a two-market regulatory strategy; approval sequencing was not disclosed.
- Competitive Landscape: The PD‑L1 bispecific and costimulatory-agonist space is actively pursued globally; LBL‑024’s differentiation would rest on being first to regulatory finish with a 4‑1BB mechanism.
- Next Steps: Continued clinical development under FDA Fast Track in first-line BTC and EP‑NEC, and NMPA review of the accepted BLA; trial readouts and filing timelines were not detailed.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding LBL‑024, including its Fast Track development, BLA review outcome, and potential to become the world’s first approved 4‑1BB antibody drug, first agonist antibody drug, and first therapeutic drug for EP‑NEC. Fast Track Designation does not guarantee approval. Actual results may differ due to risks including clinical trial outcomes, regulatory review timelines, safety profile development, and competitive dynamics.-Fineline Info & Tech
